Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rociletinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 19/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | FES | P07332 | 1/20 | 1.00 |
| ▸ | FER | P16591 | 1/20 | 1.00 |
| ▸ | ERBB3 | P21860 | 1/20 | 1.00 |
| ▸ | TEC | P42680 | 1/20 | 1.00 |
| ▸ | CLK1 | P49759 | 1/20 | 1.00 |
| ▸ | JAK3 | P52333 | 1/20 | 1.00 |
| ▸ | PTK2 | Q05397 | 1/20 | 1.00 |
| ▸ | BTK | Q06187 | 1/20 | 1.00 |
| ▸ | TNK1 | Q13470 | 1/20 | 1.00 |
| ▸ | ALK | Q9UM73 | 1/20 | 1.00 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rociletinib SCHEMBL29448192 | 1.00 | EGFR (1.00) | EGFRGAKFESFERERBB3 | |
| Rociletinib SCHEMBL29350136 | 1.00 | EGFR (1.00) | EGFRGAKFESFERERBB3 | |
| Rociletinib SCHEMBL30101824 | 0.99 | EGFR (0.99) | EGFRGAKFESFERERBB3 | |
| SCHEMBL4166347 | 0.97 | EGFR (1.00) | EGFRGAKFESFERERBB3 | |
| SCHEMBL24900776 | 0.97 | EGFR (0.94) | EGFRGAKFESFERERBB3 | |
| SCHEMBL30221331 | 0.97 | EGFR (0.94) | EGFRGAKFESFERERBB3 | |
| SCHEMBL2730294 | 0.95 | EGFR (1.00) | EGFRGAKFESFERERBB3 | |
| SCHEMBL4165883 | 0.94 | EGFR (1.00) | EGFRGAKFESFERERBB3 | |
| SCHEMBL16556502 | 0.93 | EGFR (0.87) | EGFRGAKFESFERERBB3 | |
| SCHEMBL2722575 | 0.93 | EGFR (1.00) | EGFRGAKFESFERERBB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240269136-A1 | EGFR INHIBITOR AND PERK ACTIVATOR IN COMBINATION THERAPY AND THEIR USE FOR TREATING CANCER | GENENTECH, INC. (US) | 2024-08-15 | — | — | US | claimed |
| EP-4355330-A1 | EGFR INHIBITOR AND PERK ACTIVATOR IN COMBINATION THERAPY AND THEIR USE FOR TREATING CANCER | Genentech, Inc. (US) | 2024-04-24 | — | — | EP | claimed |
| WO-2022265950-A1 | EGFR INHIBITOR AND PERK ACTIVATOR IN COMBINATION THERAPY AND THEIR USE FOR TREATING CANCER | GENENTECH, INC. (US) | 2022-12-22 | — | — | WO | claimed |
| US-20180193274-A1 | COMPOSITIONS FOR ILEO-JEJUNAL DRUG DELIVERY | PRINCIPIA BIOPHARMA INC. | 2018-07-12 | — | — | US | claimed |
| US-20170319581-A1 | Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with an EGFR inhibitor | MERCK PATENT GMBH (DE) | 2017-11-09 | — | — | US | claimed |
| EP-3236943-A1 | COMPOSITIONS FOR ILEO-JEJUNAL DRUG DELIVERY | PRINCIPIA BIOPHARMA INC. (US) | 2017-11-01 | — | — | EP | claimed |
| EP-3229806-A1 | COMBINATION OF A 6-OXO-1,6-DIHYDRO-PYRIDAZINE DERIVATIVE HAVING ANTI-CANCER ACTIVITY WITH AN EGFR INHIBITOR | Merck Patent GmbH (DE) | 2017-10-18 | — | — | EP | claimed |
| EP-3157916-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD Pharmaceuticals, Inc. (US) | 2017-04-26 | — | — | EP | claimed |
| WO-2016105582-A1 | COMPOSITIONS FOR ILEO-JEJUNAL DRUG DELIVERY | NUNN PHILIP A (US) | 2016-06-30 | — | — | WO | claimed |
| WO-2016091346-A1 | COMBINATION OF A 6-OXO-1,6-DIHYDRO-PYRIDAZINE DERIVATIVE HAVING ANTI-CANCER ACTIVITY WITH AN EGFR INHIBITOR | MERCK PATENT GMBH (DE) | 2016-06-16 | — | — | WO | claimed |
| WO-2015195228-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. (US) | 2015-12-23 | — | — | WO | claimed |
| US-20250108050-A1 | COMBINATION OF EGFR INHIBITOR AND MEK INHIBITOR FOR USE IN THE TREATMENT OF NRAS MUTATED CANCER | ASTRAZENECA AB (SE) | 2025-04-03 | — | — | US | disclosed |
| US-20240269136-A1 | EGFR INHIBITOR AND PERK ACTIVATOR IN COMBINATION THERAPY AND THEIR USE FOR TREATING CANCER | GENENTECH, INC. (US) | 2024-08-15 | — | — | US | disclosed |
| CN-118141921-A | Use of CAMK2 inhibitors for the preparation of a medicament for reducing resistance to EGFR-driven cancers | 四川大学 | 2024-06-07 | — | — | CN | disclosed |
| EP-4355330-A1 | EGFR INHIBITOR AND PERK ACTIVATOR IN COMBINATION THERAPY AND THEIR USE FOR TREATING CANCER | Genentech, Inc. (US) | 2024-04-24 | — | — | EP | disclosed |
| WO-2013138495-A1 | SOLID FORMS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-09-19 | — | — | WO | disclosed |
| WO-2013138502-A1 | SALTS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-09-19 | — | — | WO | disclosed |
| WO-2013138502-A1 | SALTS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-09-19 | — | — | WO | disclosed |
| US-20120149687-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| WO-2012061299-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250108050-A1 | COMBINATION OF EGFR INHIBITOR AND MEK INHIBITOR FOR USE IN THE TREATMENT OF NRAS MUTATED CANCER | NRAS, KRAS, EGFR | EGFR 3/4885GAK 129/4885FES 1248/4885 |
| US-20120149687-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ABCG2, CYP3A5, CYP3A43 | EGFR 2849/4885GAK 1852/4885FES 1328/4885 |
| US-20180193274-A1 | COMPOSITIONS FOR ILEO-JEJUNAL DRUG DELIVERY | BTK, LCK, DSTYK | EGFR 228/4885GAK 234/4885FES 636/4885 |
| US-20170319581-A1 | Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with an EGFR inhibitor | EGFR, ERBB4, ERBB2 | EGFR 1/4885GAK 563/4885FES 325/4885 |
| US-20240269136-A1 | EGFR INHIBITOR AND PERK ACTIVATOR IN COMBINATION THERAPY AND THEIR USE FOR TREATING CANCER | EGFR, ERBB2, ERBB4 | EGFR 1/4885GAK 517/4885FES 1419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.